HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment

Abstract Approximately a half of breast tumors classified as HER2-negative exhibit HER2-low-positive expression. We recently described a high instability of HER2-low-positive expression from primary breast cancer (BC) to relapse. Previous studies reporting discordance in HER2 status between baseline...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Federica Miglietta, Gaia Griguolo, Michele Bottosso, Tommaso Giarratano, Marcello Lo Mele, Matteo Fassan, Matilde Cacciatore, Elisa Genovesi, Debora De Bartolo, Grazia Vernaci, Ottavia Amato, Francesca Porra, PierFranco Conte, Valentina Guarneri, Maria Vittoria Dieci
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Portfolio 2022-05-01
Saila:npj Breast Cancer
Sarrera elektronikoa:https://doi.org/10.1038/s41523-022-00434-w
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak